Tamoxifen loaded poly (εcaprolactone) based injectable microspheres for breast cancer

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue 4, 2010, Pages 189-195

  Jagadeesh, Hiremath G ^a   Kusm Devi, V ^b  

^a East West College of Pharmacy   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Breast cancer; MCF 7 cells; Microspheres; Poly ( caprolactone); Tamoxifen

Indexed keywords

MICROSPHERE; PHOSPHATE BUFFERED SALINE; POLYCAPROLACTONE; TAMOXIFEN;

ANALYZER; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; LOADING DRUG DOSE; MASTER SIZE ANALYZER; MORPHOLOGY; PARTICLE SIZE; PH; SCANNING ELECTRON MICROSCOPE;

EID: 79955648029     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Feng SS, Chien S. Chemotherapeutic engineering: Application and further development of chemical principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003;58:4087-5014.
2. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
3. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996; 271:1079-80.
4. Au JLS, Jang SH, Zheng J. Determinants of drug delivery and transport in solid tumors. J Control Release 2001; 74:31-46.
5. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48:2641-58.
6. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Accad Sci 1998; 95:4607-12.
7. Macgregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50:151-96.
8. Szyczak J, Milewicz A, Thijssen JHH, Blankenstein MA, Daroszewski J Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;63 319-21.
9. Buckley M, Goa K. Tamoxifen a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1989;37:451-90.
10. Daniel PC, Gaskel, J, Bishop H.; Campbell, C.; Nicholson, R. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumors. Eur J Cancer Clin Oncol 1981; 17:1183-89.
11. Jordan VC, Collins MM, Rowsby L, Prestwich G J. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. Endocrinol 1977; 75:305-16.
12. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly caprolactone nanoparticles containing griseofulvin. Int J Pharm 2005; 294:261-67.
13. Rich J K, Ahola P, Yli-Urpo M, Kiesvaara AJ, Seppala, J,. Effect of molecular weight of poly (ecaprolactone co-lactide) on toremifine citrate release from copolymer/silica xerogel composites. Int J Pharm 2001; 212:121-130.
14. Hiremath J G, Kusum Devi V, Kshama Devi, Domb A. Biodegradable Poly(sebacic acid-co-ricinoleic-ester anhydride) tamoxifen citrate implants: Preparation and In Vitro Characterization. J App Poly Sci 2008; 107:2745-54.
15. Brewster ME, Paran Y, Rushkin E, Biegon A, Pop E, Degani H. Evaluation of the anticancer action of a permanently charged tamoxifen derivative, tamoxifen methiodide: an MRI study. Int J Pharm 1997; 153(11):147-57.
16. Dhiman H, Ray A R, Panda A K. Characterization and evaluation of chitosan matrix for in vitro growth of MCF-7 breast cancer cell lines. Biomaterials 2005;26:979-86.
17. Reddel RR, Murphy LC, Hall R E, Sutherland R L. Differential sensitivity of human cell lines to the growth inhibitory effects of tamoxifen. Can Res 1985; 45:1525-30.
18. Hu FX, Neoh, KG.; Kang E.T. Synthesis and in vitro evaluation of tamoxifen loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006;27:5725-36.
19. Elkharraz K, Faisant N, Guse C, Siepmann F, Yegin BA, Oger JM, et. al. Paclitaxel loaded microparticles and implants for the treatment of brain cancer: Preparation and physical characterization. Int J Pharm 2006;137:127-35.
20. Elzein T, Nasser-Eddine, M, Delaite C, Bistac S, Dumas P. FTIR study of polycaprolactone chain organization at interfaces. J Colloid Interface Sci 2004; 273:381-87.
21. Dubernet C. Thermo analysis of microspheres. Thermo chim Acta 1995;248:259-69.
22. Chawla SJ, Amiji MM. Biodegradable poly caprolactone nanoparticles for tumor targeted delivery of tamoxifen. Int J Pharm 2002;249:127-38.
23. Jameela SR, Suma, N, Jayakrishnan A. Protein release from poly (ε-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: A comparative study. J Biomater Sci Polym 1997;8(6):457-66.
24. Pitt C G. Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, Inc. New York; 1990. p. 71-119.
25. Langer R, Folkman F. Polymers for the sustained release of proteins and other macromolecules. Nature 1976; 263:797-800.
26. Langer R. New methods of drug delivery. Science 1990; 249:1527-33.
27. Jeong JC, Lee J, Cho K. Effects of crystalline microstructure on drug release behavior of polycaprolactone microspheres. J Control Release 2003; 92:249-58.